211At-MABG in Adults With Advanced Neuroendocrine Cancers

NCT07661420 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Pheochromocytoma
Paraganglioma
Neuroendocrine Tumors
Medullary Thyroid Cancer
Bronchial Carcinoid
Gastroenteropancreatic Neuroendocrine Neoplasm

Interventions

DRUG: 1 MBq/k of 211At-MABG Fractionated
DRUG: 2 MBq/k1 of 211At-MABG Fractionated
DRUG: 4 MBq/k of 211At-MABG Fractionated

Sponsor

University of Pennsylvania

Collaborators

[object Object]
[object Object]